Clinical Trials

80 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04712851 2026-03-10

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

25 enrolled

Uterine Cervical Dysplasia

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

18 enrolled

Endometrial Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05761951 2026-02-11

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

8 enrolled

Endometrial Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

32 enrolled

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT05082259 2026-02-10

ASTEROID

Phase 1 Recruiting

61 enrolled

BreastGynecologic

Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Adenocarcinoma, Uterine Cervical Neoplasms

NCT06640283 2025-12-24

ANA

GastrointestinalGynecologic

150 enrolled

Anal Canal Carcinoma, Uterine Cervical Neoplasms

NCT06266338 2025-12-22

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

30 enrolled

Uterine Cervical Neoplasms

NCT07261683 2025-12-19

Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

20 enrolled

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT07290894 2025-12-18

MITO VULVA-01

80 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Vulvar Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT07223424 2025-11-10

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

480 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Recurrence, Endometrial Neoplasms

NCT03029403 2025-09-19

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

47 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04387227 2025-09-18

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

22 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05036681 2025-09-17

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 8 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT05156268 2025-08-17

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

26 enrolled

GynecologicSarcoma

Endometrial Carcinosarcoma

NCT05114421 2025-08-07

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

30 enrolled

High Grade Fallopian Tube Serous Adenocarcinoma

NCT06513624 2025-07-25

ETC-159-02

Phase 1 Recruiting

16 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05920798 2025-06-22

FRAPPE

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02899793 2025-06-11

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

25 enrolled 15 charts

Endometrial Neoplasms

NCT02520154 2025-06-08

Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled 12 charts

Fallopian Tube Neoplasms

NCT03835819 2025-05-15

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

18 enrolled 17 charts

Endometrial Neoplasms

NCT04919629 2025-05-11

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06502743 2025-04-03

PENELOPE

92 enrolled

Endometrial Neoplasms

NCT02644369 2025-03-26

INSPIRE

BreastDermatologicGynecologic

100 enrolled

Carcinoma, Ovarian Epithelial, Melanoma, Triple Negative Breast Neoplasms

NCT04357873 2025-02-19

PEVOsq

GastrointestinalGenitourinaryGynecologicHead & Neck

112 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT06805864 2025-02-03

BROTHER

Phase 2 Not yet recruiting

45 enrolled

Uterine Cervical Neoplasms

NCT02630823 2025-01-03

MK-3475 Immunotherapy in Endometrial Carcinoma

Phase 1 Completed

10 enrolled 9 charts

Endometrial Neoplasms

NCT05200559 2024-12-05

T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors

70 enrolled

Turcot syndrome, Carcinoma, Ovarian Epithelial

NCT04713514 2024-12-02

TEDOVA

180 enrolled

Ovarian Neoplasms, Recurrence

NCT03596281 2024-10-18

PEMBOV

Phase 1 Completed

47 enrolled

Phase NA Not yet recruiting

Ovarian Neoplasms

NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

10 enrolled

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Phase 2 Terminated

17 enrolled 12 charts

Uterine Cervical Neoplasms

NCT05635344 2024-04-17

A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

20 enrolled

Recurrence, Gestational Trophoblastic Disease

NCT03732950 2024-04-15

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

5 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03425565 2024-04-12

PEACOCC

Phase 2 Unknown

48 enrolled

Phase NA Active not recruiting

Clear Cell Tumor

NCT05368207 2024-03-13

Pemb-HT

1 enrolled

Ovarian Neoplasms, Carcinoma, Small Cell

NCT03012620 2024-02-28

AcSé

CNSEndocrineGynecologicHead & NeckLymphoidSarcoma

334 enrolled

Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Lymphoma, Extranodal NK-T-Cell

NCT02766582 2024-02-26

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

29 enrolled 9 charts

Phase EARLY_PHASE1 Completed

Ovarian Neoplasms

NCT02728830 2024-02-21

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

39 enrolled 16 charts